{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:35Z","timestamp":1786982375979,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s12325-016-0326-5","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T06:15:10Z","timestamp":1460614510000},"page":"848-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials"],"prefix":"10.1007","volume":"33","author":[{"given":"Kathrin","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Brunell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"issue":"Suppl 2","key":"326_CR1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.2337\/diabetes.54.suppl_2.S32","volume":"54","author":"NA Sherry","year":"2005","unstructured":"Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes. 2005;54(Suppl 2):S32\u20139.","journal-title":"Diabetes"},{"key":"326_CR2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00125-005-0100-8","volume":"49","author":"EB Tsai","year":"2006","unstructured":"Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261\u201370.","journal-title":"Diabetologia"},{"key":"326_CR3","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1210\/jc.2012-1561","volume":"97","author":"RW Beck","year":"2012","unstructured":"Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97:4383\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"326_CR4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"326_CR5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2337\/diacare.19.7.744","volume":"19","author":"R Klein","year":"1996","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care. 1996;19:744\u201350.","journal-title":"Diabetes Care"},{"key":"326_CR6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2337\/diacare.11.7.567","volume":"11","author":"Diabetes Control and Complications Trial Research Group","year":"1988","unstructured":"Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care. 1988;11:567\u201373.","journal-title":"Diabetes Care"},{"key":"326_CR7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","volume":"4","author":"AA Young","year":"1997","unstructured":"Young AA. Amylin\u2019s physiology and its role in diabetes. Curr Opin Endocrinol Diab. 1997;4:282\u201390.","journal-title":"Curr Opin Endocrinol Diab."},{"key":"326_CR8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0006-8993(91)91644-G","volume":"539","author":"WT Chance","year":"1991","unstructured":"Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ, Fischer JE. Anorexia following the intrahypothalamic administration of amylin. Brain Res. 1991;539:352\u20134.","journal-title":"Brain Res"},{"key":"326_CR9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0168-8227(92)90142-E","volume":"18","author":"G Panagiotidis","year":"1992","unstructured":"Panagiotidis G, Salehi AA, Westermark P, Lundquist I. Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract. 1992;18:167\u201371.","journal-title":"Diabetes Res Clin Pract"},{"key":"326_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","volume":"45","author":"AA Young","year":"1996","unstructured":"Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism. 1996;45:1\u20133.","journal-title":"Metabolism."},{"key":"326_CR11","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","volume":"51","author":"MS Fineman","year":"2002","unstructured":"Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636\u201341.","journal-title":"Metabolism."},{"key":"326_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/15209150260007390","volume":"4","author":"SV Edelman","year":"2002","unstructured":"Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther. 2002;4:175\u201389.","journal-title":"Diabetes Technol Ther."},{"key":"326_CR13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","volume":"7","author":"C Weyer","year":"2001","unstructured":"Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353\u201373.","journal-title":"Curr Pharm Des"},{"key":"326_CR14","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","volume":"29","author":"S Edelman","year":"2006","unstructured":"Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29:2189\u201395.","journal-title":"Diabetes Care"},{"key":"326_CR15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2337\/diacare.18.8.1179","volume":"18","author":"OG Kolterman","year":"1995","unstructured":"Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995;18:1179\u201382.","journal-title":"Diabetes Care"},{"key":"326_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","volume":"40","author":"MF Kong","year":"1997","unstructured":"Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40:82\u20138.","journal-title":"Diabetologia"},{"key":"326_CR17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","volume":"48","author":"B Nyholm","year":"1999","unstructured":"Nyholm B, Orskov L, Hove KY, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999;48:935\u201341.","journal-title":"Metabolism."},{"key":"326_CR18","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.2000.278.6.G946","volume":"278","author":"M Samsom","year":"2000","unstructured":"Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278:G946\u201351.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl 2","key":"326_CR19","first-page":"A240","volume":"45","author":"C Weyer","year":"2002","unstructured":"Weyer C, Maggs D, Kim D, et al. Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to regular insulin or insulin lispro in patients with type 1 diabetes: a dose-timing study. Diabetologia. 2002;45(Suppl 2):A240.","journal-title":"Diabetologia"},{"key":"326_CR20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204\u201312.","journal-title":"Diabet Med"},{"key":"326_CR21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","volume":"27","author":"B Conway","year":"2010","unstructured":"Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398\u2013404.","journal-title":"Diabet Med"},{"key":"326_CR22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/dc09-0114","volume":"32","author":"JP Bremer","year":"2009","unstructured":"Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513\u20137.","journal-title":"Diabetes Care"},{"key":"326_CR23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5694\/j.1326-5377.2002.tb04754.x","volume":"177","author":"ME Craig","year":"2002","unstructured":"Craig ME, Handelsman P, Donaghue KC, et al. Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust. 2002;177:235\u20138.","journal-title":"Med J Aust"},{"key":"326_CR24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(94)91336-6","volume":"344","author":"I Cranston","year":"1994","unstructured":"Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283\u20137.","journal-title":"Lancet"},{"key":"326_CR25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/diacare.15.3.318","volume":"15","author":"RA DeFronzo","year":"1992","unstructured":"DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318\u201368.","journal-title":"Diabetes Care."},{"key":"326_CR26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jdiacomp.2011.10.003","volume":"25","author":"WC Duckworth","year":"2011","unstructured":"Duckworth WC, Abraira C, Moritz TE, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complic. 2011;25:355\u201361.","journal-title":"J Diabetes Complic"},{"key":"326_CR27","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2337\/db10-0103","volume":"59","author":"RJ McCrimmon","year":"2010","unstructured":"McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes. 2010;59:2333\u20139.","journal-title":"Diabetes"},{"key":"326_CR28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF02913083","volume":"21","author":"M Verma","year":"2006","unstructured":"Verma M, Paneri S, Badi P, Raman PG. Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity. Indian J Clin Biochem. 2006;21:142\u20136.","journal-title":"Indian J Clin Biochem"},{"issue":"Suppl 1","key":"326_CR29","first-page":"A113","volume":"48","author":"M Fineman","year":"1999","unstructured":"Fineman M, Bahner A, Gottleib A, Kolterman O. Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes. Diabetes. 1999;48(Suppl 1):A113\u20134 (Abstr 0489).","journal-title":"Diabetes"},{"key":"326_CR30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","volume":"25","author":"F Whitehouse","year":"2002","unstructured":"Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724\u201330.","journal-title":"Diabetes Care"},{"key":"326_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","volume":"113","author":"R Ratner","year":"2005","unstructured":"Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005;113:199\u2013204.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"326_CR32","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/diacare.22.12.1956","volume":"22","author":"KS Bryden","year":"1999","unstructured":"Bryden KS, Neil A, Mayou RA, Peveler RC, Fairburn CG, Dunger DB. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care. 1999;22:1956\u201360.","journal-title":"Diabetes Care"},{"key":"326_CR33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.2337\/diacare.17.10.1178","volume":"17","author":"WH Polonsky","year":"1994","unstructured":"Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care. 1994;17:1178\u201385.","journal-title":"Diabetes Care"},{"key":"326_CR34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"9","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799\u2013812.","journal-title":"Diabetes Obes Metab"},{"key":"326_CR35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","volume":"280","author":"JQ Purnell","year":"1998","unstructured":"Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280:140\u20136.","journal-title":"JAMA."},{"key":"326_CR36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00024677-200302010-00004","volume":"2","author":"JQ Purnell","year":"2003","unstructured":"Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol. 2003;2:33\u201347.","journal-title":"Treat Endocrinol."},{"key":"326_CR37","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","volume":"98","author":"RS Weinstock","year":"2013","unstructured":"Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013;98:3411\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"326_CR38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ecl.2010.05.003","volume":"39","author":"PE Cryer","year":"2010","unstructured":"Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010;39:641\u201354.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"326_CR39","first-page":"467","volume":"141","author":"M Lorenzi","year":"1984","unstructured":"Lorenzi M, Bohannon N, Tsalikian E, Karam JH. Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia. West J Med. 1984;141:467\u201371.","journal-title":"West J Med"},{"key":"326_CR40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1463-1326.2004.00417.x","volume":"7","author":"SA Amiel","year":"2005","unstructured":"Amiel SA, Heller SR, Macdonald IA, et al. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab. 2005;7:504\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"326_CR41","first-page":"1083","volume":"81","author":"B Nyholm","year":"1996","unstructured":"Nyholm B, Moller N, Gravholt CH, et al. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:1083\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"326_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/dia.2006.0013","volume":"9","author":"D Karl","year":"2007","unstructured":"Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9:191\u20139.","journal-title":"Diabetes Technol Ther."},{"key":"326_CR43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1463-1326.2010.01201.x","volume":"12","author":"R Pencek","year":"2010","unstructured":"Pencek R, Roddy T, Peters Y, et al. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study. Diabetes Obes Metab. 2010;12:548\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"326_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","volume":"2","author":"J Pullman","year":"2006","unstructured":"Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 2006;2:203\u201312.","journal-title":"Vasc Health Risk Manag."},{"key":"326_CR45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3810\/pgm.2013.05.2635","volume":"125","author":"K Herrmann","year":"2013","unstructured":"Herrmann K, Frias JP, Edelman SV, et al. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013;125:136\u201344.","journal-title":"Postgrad Med"},{"issue":"Suppl 1","key":"326_CR46","first-page":"A118","volume":"54","author":"R Guthrie","year":"2005","unstructured":"Guthrie R, Karl DM, Wang Y, Lorenzi G. In an open-label clinical study pramlintide lowered A1c, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy. Diabetes. 2005;54(Suppl 1):A118.","journal-title":"Diabetes"},{"key":"326_CR47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","volume":"169","author":"DM Nathan","year":"2009","unstructured":"Diabetes Control Complications Trial Research Group\/Epidemiology of Diabetes Interventions and Complications Research Group, Nathan DM, Zinman B. Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983\u20132005). Arch Intern Med. 2009;169:1307\u201316.","journal-title":"Arch Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0326-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T13:14:19Z","timestamp":1600434859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0326-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0326-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}